| Biotech Co.* (Country; Symbol) |
Pharma Co. (Country) |
Type/Product Area | Terms/Details (Date) |
| MAY 29 31 | |||
| DxS Ltd.* (UK) | Boehringer Ingelheim GmbH (Germany) | Agreement under which DxS will provide a companion diagnostic test kit for Boehringer Ingelheim's compound BIBW 2992 to identify mutations of the epidermal growth factor receptor in patients with non-small-cell lung cancer | Financial terms were not disclosed (5/29) |
| JUNE 1 25 | |||
| Adimab Inc.* | Merck & Co. Inc. and Roche (Switzerland) | Entered separate antibody deals with the pharmaceutical companies | Adimab will receive various up-front payments, preclinical milestones and licensing fees; it also is eligible to receive clinical development milestones, commercial milestones and royalties (6/16) |
| Amalyte Pharmaceuticals LLC* | Meiji Seika Kaisha Ltd. (Japan) | Worldwide alliance to discover, develop and commercialize a lead compound, ME3301, and a novel class of dual-acting anti-inflammatory compounds for a variety of applications | Amalyte will have exclusive rights to develop and commercialize collaboration products worldwide, except in Japan and several Asian countries (6/8) |
| Aposense Ltd.* | GlaxoSmithKline plc (UK) | Collaboration to evaluate the potential of Aposense's PET tracer ML-10 in monitoring drug activity in clinical studies of cancer therapies | The project is intended to assess the contribution of ML-10 in accelerating clinical development of cancer therapies (6/8) |
| Cerep SA (France; Paris:CER) | Eli Lilly and Co. | Agreement for its expanded kinase assay platform for research into undisclosed drug targets | The agreement builds on a prior agreement between the two companies for access to Cerep's GPCRs portfolio (6/15) |
| Chroma Therapeutics Ltd.* (UK) | GlaxoSmithKline plc (UK) | Agreement for Chroma to apply its chemical motif technology for targeting small molecules directly into macrophages, to develop treatments for autoimmune and other inflammatory diseases | The collaboration involves four programs currently at the discovery stage; the deal is worth $1B if all four reach the market and achieve specified levels of sales (6/23) |
| Concert Pharmaceuticals Inc.* | GlaxoSmithKline plc (UK) | Multiproduct collaboration that includes CTP-518, an HIV protease inhibitor, and the application of Concert's deuterium chemistry platform to three undisclosed GSK compounds | Concert gets $35M up front, including a $16.7M equity investment; development, regulatory and commercial milestones could push the deal to more than $1B (6/2) |
| DiaGenic ASA (Norway; OSLO: DIAG) | Merz Pharmaceuticals GmbH (Germany) | Option agreement to gain access to biomarkers for mild cognitive impairment | Merz also will receive an option for non-exclusive rights to further biomarkers; financial details were not disclosed (6/24) |
| Merck & Co.*** | AstraZeneca plc (UK) | Collaboration to determine the efficacy of a joint regimen of compounds from each company in treating cancer in a Phase I trial | Data suggests that MK-2206 from Merck and AZD6244 from AstraZeneca may be more effective if dosed together; the companies will share co-administration expenses for the trial (6/1) |
| NeurogesX Inc. (NGSX) | Astellas Pharma Inc. (Japan) | Agreement for European rights to Qutenza | The deal is potentially worth $145.5M, including up-front, milestone and option fees, and double-digit royalties on sales (6/22) |
| Orexigen Therapeutics Inc. (OREX) | GlaxoSmithKline plc (UK) | Licensing agreement for intellectual property relating to bupropion | The deal involves up-front and milestone payments (6/11) |
| Penwest Pharmaceuticals Co. (PPCO) | Otsuka Pharmaceutical Co. Ltd. (Japan) | Research and development agreement to develop a formulation of an undisclosed Otsuka compound using Penwest's TIMERx drug delivery technology | Penwest will receive undisclosed fees and payments (6/17) |
| Raptor Pharmaceuticals Corp. (OTC BB: RPTP) | F. Hoffmann-La Roche Ltd. (Switzerland) | Collaboration to evaluate Raptor's NeuroTrans platform for therapeutic delivery across the blood-brain barrier | Roche gets exclusive worldwide rights to NeuroTrans for delivery of diagnostic and therapeutic molecules and will fund studies of select molecules attached to the platform (6/9) |
| Regeneron Pharmaceuticals Inc. (REGN) | Novartis AG (Switzerland) | License agreement relating to two antibody programs | Regeneron had the right to opt in on Novartis' interleukin-1 antibody, and Novartis had the right to opt in on Regeneron's second-generation interleukin-1 Trap program; Regeneron waived its right to opt in on the anti-interleukin antibody canakinumab and will instead receive royalties, while Novartis will receive royalties on the second-generation interleukin-1 Trap program (6/11) |
| Valeant Pharmaceuticals International (NYSE:VRX) | Schering-Plough Corp. | Exclusive option agreement for taribavirin, which is in Phase II development for chronic hepatitis C, in Japan | Upon exercising the option and entering into the exclusive license agreement, Schering- Plough would provide a $2M up-front payment to Valeant and pay mid-single digit royalties on net sales of taribavirin in Japan (6/1) |
| Vitae Pharmaceuticals Inc.* | Boehringer Ingelheim GmbH (Germany) | Deal aimed at disease-modifying drugs against Alzheimer's disease | The deal is worth $42M in cash, an equity investment and research funding, as well as $200M in pre-commercial milestones for the first compound (6/15) |
| Xenon Pharmaceuticals Inc.* | Merck & Co. Inc. | Cardiovascular drug discovery partnership | Deal could bring in up to $94.5M for the first therapeutic target and up to $89.5M for each subsequent target that is secreted for drug discovery (6/11) |
|
Notes: # The information in the chart does not cover agricultural agreements or those between biotech companies. * Private companies are indicated with an asterisk.** Denotes the date the item ran in BioWorld International. *** Pharmaceutical company deal included in this chart due to its relevance to the biotech industry.Unless otherwise noted, stock symbols listed are on the Nasdaq market. NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board. | |||